Business Standard

Aurobindo Pharma receives US FDA approval for sevelamer oral suspension

Product is indicated to control serum phosphorus in patients with chronic kidney disease on dialysis

Lupin gets US FDA nod for antibacterial drug azithromycin suspension
Premium

BS B2B Bureau Hyderabad
Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (FDA) to manufacture sevelamer carbonate oral suspension (0.8 gm and 2.4 gm), which is a therapeutic equivalent generic version of Genzyme’s Renvela oral suspension. The company plans to launch the product very soon. 

Sevelamer carbonate oral suspension is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. The approved product has an estimated market size of $ 140 million for the twelve months ending April 2017, according to IMS.

This is Aurobindo’s 116th ANDA (including 19 tentative approvals) to be approved

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in